TY - JOUR
T1 - PHARMACOKINETIC INTERACTION BETWEEN NIFEDIPINE AND PROPRANOLOL
AU - ZYLBER‐KATZ, E.
AU - TURETZ‐ABRAMOVITCH, M.
AU - KOREN, G.
AU - LEVY, M.
PY - 1988
Y1 - 1988
N2 - Summary— In 8 healthy volunteers, single‐dose nifedipine pharmacokinetics were compared with and without the coadministration of propranolol. An elevation of the mean Cmax was found, from 73.9±14.1 when nifedipine was taken alone, to 115.7±12.1 (SE) ng/ml (P<0.02) when the agent was combined with propranolol. The AUC0‐∞ increased as well, from 287.1±33.5 to 363.0±54.3 (SE) (μg.hr)/1 (P<0.01), indicating an increase in bioavailability. Propranolol treatment did not significantly affect the nifedipine half‐life (α or β phase) or the estimated volume of distribution, whereas systemic clearance tended to decrease in 6 of the subjects. The most likely explanation for increased bioavailability of nifedipine when coadministered with propranolol is by a reduction of the hepatic ± first‐pass ± clearance, as a result of changes in hepatic blood flow. 1988 Société Française de Pharmacologie et de Thérapeutique
AB - Summary— In 8 healthy volunteers, single‐dose nifedipine pharmacokinetics were compared with and without the coadministration of propranolol. An elevation of the mean Cmax was found, from 73.9±14.1 when nifedipine was taken alone, to 115.7±12.1 (SE) ng/ml (P<0.02) when the agent was combined with propranolol. The AUC0‐∞ increased as well, from 287.1±33.5 to 363.0±54.3 (SE) (μg.hr)/1 (P<0.01), indicating an increase in bioavailability. Propranolol treatment did not significantly affect the nifedipine half‐life (α or β phase) or the estimated volume of distribution, whereas systemic clearance tended to decrease in 6 of the subjects. The most likely explanation for increased bioavailability of nifedipine when coadministered with propranolol is by a reduction of the hepatic ± first‐pass ± clearance, as a result of changes in hepatic blood flow. 1988 Société Française de Pharmacologie et de Thérapeutique
KW - nifedipine
KW - pharmacokinetic interaction
KW - propranolol
UR - http://www.scopus.com/inward/record.url?scp=0023907077&partnerID=8YFLogxK
U2 - 10.1111/j.1472-8206.1988.tb00618.x
DO - 10.1111/j.1472-8206.1988.tb00618.x
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 3371839
AN - SCOPUS:0023907077
SN - 0767-3981
VL - 2
SP - 29
EP - 35
JO - Fundamental and Clinical Pharmacology
JF - Fundamental and Clinical Pharmacology
IS - 1
ER -